Matching articles for "IBS"
Issue 1290 · July 14, 2008
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation

Lubiprostone (Amitiza) , which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with…

Med Lett Drugs Ther. 2008 Jul 14; 50(1290):53-4
Lubiprostone (Amitiza) , which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Issue 1260 · May 7, 2007 Free
In Brief: Tegaserod (Zelnorm) Withdrawn

Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of…

Med Lett Drugs Ther. 2007 May 7; 49(1260):40
Tegaserod maleate ( Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women, 1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect. 2 The FDA now has requested that the manufacturer stop marketing the drug based on an unpublished postmarketing analysis of earlier clinical trials that showed a higher rate of serious cardiovascular events (including angina, myocardial infarction and stroke) in patients who took tegaserod compared to placebo. Among more than 11,600 patients treated with tegaserod for 1-3 months, 13 (0.11%) had a confirmed ischemic event compared to only 1 patient (0.01%) among more than 7000 treated with placebo. The mechanism by which tegaserod would cause cardiovascular ischemia is unknown; serotonin 5-HT 1 receptor agonists used to treat migraine, such as sumatriptan (Imitrex) , can constrict coronary arteries, and tegaserod has some affinity for 5-HT 1 receptors. 3 Tegaserod may still be available, possibly through a special access program, for patients who do not have other treatment options. 1. Tegaserod maleate (Zelnorm) for IBS with constipation. Med Lett Drugs Ther 2002; 44:79. 2. Drugs for irritable bowel syndrome. Treat Guidel Med Lett 2006; 4:11. 3. AJ Busti et al. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24:526. Download U.S. English
Issue 43 · March 1, 2006
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort…

Treat Guidel Med Lett. 2006 Mar; 4(43):11-6
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort and altered bowel habits.
Issue 1139 · September 16, 2002
Tegaserod Maleate (Zelnorm) for IBS with Constipation

Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is…

Med Lett Drugs Ther. 2002 Sep 16; 44(1139):79-80
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex) , which was withdrawn previously because of toxicity, will soon be available again for women with severe diarrhea-predominant IBS ( Medical Letter 2002; 44:67 ).
Issue 1136 · August 5, 2002
Alosetron (Lotronex) revisited

The FDA recently announced that it will permit reintroduction of alosetron hydrochloride ( Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from…

Med Lett Drugs Ther. 2002 Aug 5; 44(1136):67-8
The FDA recently announced that it will permit reintroduction of alosetron hydrochloride ( Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from the market because of severe gastrointestinal toxicity. The reintroduced drug will have a 50% lower starting dose, a narrower indication and some other marketing restrictions ( www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm ).
Issue 1081 · June 26, 2000
Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome

Alosetron hydrochloride (Lotronex - Glaxo Welcome) , a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is…

Med Lett Drugs Ther. 2000 Jun 26; 42(1081):53-4
Alosetron hydrochloride (Lotronex - Glaxo Welcome) , a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.